AMTI News and Press, Applied Molecular Transport Inc. From 07/06/22

Gainers: Inspira Technologies Oxy ( IINN ) +98% . Cano Health CANO +18% . Veru VERU +16% . Amylyx Pharmaceuticals ( AMLX ) +13% . Equillium ( EQ ) +12% . Losers: Applied Molecular Transport AMTI -26% . HTG Molecular D...

The clinical-stage biotech Applied Molecular Transport ( NASDAQ: AMTI ) dropped ~38% in the pre-market Wednesday after the company said its lead candidate AMT-101 failed to outperform in combination with AbbVie’s ( ABBV ) blockbuster drug Humira in a Phase 2 trial...

Applied Molecular Transport ( AMTI ) -40% erasing yesterday's gain on ulcerative colitis candidate data . Kornit Digital ( KRNT ) -24% after pre-announcing weak Q2 results, Citi slashes price target . Lottery.com ( LTRY ) -15% . SOS ( SOS ...

– Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in patients receiving placebo plus adalimumab at week 8 – Post hoc analysis of patients with shorter duration of ulcerative coli...

Shares of Applied Molecular Transport ( NASDAQ: AMTI ) are up ~4% in after-hours trading after the company said it will release top-line results from a phase 2 trial of AMT-101 for ulcerative colitis before Wednesday's opening bell. The trial enrolled biologic-naiv...

SOUTH SAN FRANCISCO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selective, oral fusion of IL-10) with anti-TN...

SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced its participation in fireside chats at the following investor conferences: Event: Jefferies Global Heal...

Applied Molecular Transport (NASDAQ:AMTI) stock has lost 5.2% to $4.05 in Wednesday morning trade, after the clinical-stage biopharmaceutical company said it would prioritize its resources on its lead clinical programs, reduce its workforce and change up its management team. AMTI to...

Company streamlines to prioritize resources on key proprietary clinical programs, including plans to advance AMT-101 into Phase 3 for chronic pouchitis Three Phase 2 top-line readouts for oral AMT-101 in ulcerative colitis (UC) and rheumatoid arthritis (RA) anticipated in 2022, ...

Applied Molecular Transport press release (NASDAQ:AMTI): Q1 GAAP EPS of -$1.10 misses by $0.35. As of March 31, 2022, cash and cash equivalents were $126.5 million. The Company believes its cash and cash equivalents will be sufficient to allow the Company to fund its current operating plan fo...